JUL 30, 2019
Macular Disease, Retina/Vitreous
In this interview from ASRS 2019, Dr. Jeffrey Heier describes the results of the PRO-CON study assessing prophylactic aflibercept in high-risk dry AMD patients. The trial compared the conversion rate to neovascular AMD after quarterly aflibercept injections versus sham treatment. During the 2-year study, aflibercept did not affect the conversion rate, which was approximately 9% to 11% during the study period. A subgroup analysis suggests that those who recently converted to wet AMD in the nontreated fellow eye had higher conversion rates compared with fellow eyes that have had the disease for 2 years or longer.
Relevant Financial Disclosures: Dr. Heier is a consultant for and receives grant support from Regeneron.